Frequency of fks mutations among candida glabrata isolates from a 10-Year global collection of bloodstream infection isolates

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 1, 2014, Pages 577-580

  Castanheira, Mariana ^a   Woosley, Leah N ^a   Messer, Shawn A ^a   Diekema, Daniel J ^b   Jones, Ronald N ^a   Pfaller, Michael A ^a,b  

^a JMI LABORATORIES   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 BETA GLUCAN SYNTHASE; ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; MICAFUNGIN;

AMINO ACID SUBSTITUTION; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BLOODSTREAM INFECTION; CANDIDA GLABRATA; CONTROLLED STUDY; FKS GENE; FUNGAL GENE; FUNGUS ISOLATION; FUNGUS MUTATION; GENE MUTATION; MINIMUM INHIBITORY CONCENTRATION; MUTATION RATE; NONHUMAN; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; CANDIDA GLABRATA; ECHINOCANDINS; LIPOPEPTIDES; MICROBIAL SENSITIVITY TESTS; MUTATION;

EID: 84891506996     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01674-13     Document Type: Article

References (14)

1. Katiyar SK, Alastruey-Izquierdo A, Healey KR, Johnson ME, Perlin DS, Edlind TD. 2012. Fks1 and Fks2 are functionally redundant but differentially regulated in Candida glabrata: Implications for echinocandin resistance. Antimicrob. Agents Chemother. 56:6304-6309. http://dx.doi.org/10.1128/AAC.00813- 12.
2. Alexander BD, Johnson MD, Pfeiffer CD, Jimenez-Ortigosa C, Catania J, Booker R, Castanheira M, Messer SA, Perlin DS, Pfaller MA. 2013. Increasing echinocandin resistance in Candida glabrata: Clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin. Infect. Dis. 56:1724-1732. http://dx.doi.org/10.1093/cid/cit136.
3. Castanheira M, Woosley LN, Pfaller MA, Diekema DJ, Messer SA, Jones RN. 2010. Low prevalence of fks1 hotspot 1 mutations in a worldwide collection of Candida spp. Antimicrob. Agents Chemother. 54:2655- 2659. http://dx.doi.org/10. 1128/AAC.01711-09.
4. Ostrosky-Zeichner L. 2013. Candida glabrata and FKS mutations: Witnessing the emergence of the true multidrug-resistant Candida. Clin. Infect. Dis. 56:1733-1734. http://dx.doi.org/10.1093/cid/cit140.
5. Pfaller MA, Castanheira M, Diekema DJ, Messer SA, Jones RN. 2011. Triazole and echinocandin wild-type MIC distributions with epidemiological cutoff values for six uncommon species of Candida. J. Clin. Microbiol. 49:3800-3804. http://dx.doi.org/10.1128/JCM.05047-11.
6. Turnidge J, Kahlmeter G, Kronvall G. 2006. Statistical characterization of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. Clin. Microbiol. Infect. 12:418-425. http: //dx.doi.org/10.1111/j.1469-0691.2006.01377.x.
7. Clinical and Laboratory Standards Institute. 2008. M27-A3. Reference method for broth dilution antifungal susceptibility testing of yeasts, 3rd ed. Clinical and Laboratory Standards Institute, Wayne, PA.
8. Clinical and Laboratory Standards Institute. 2012. M27-S4. Reference method for broth dilution antifungal susceptibility testing of yeasts, 4th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
9. Healey KR, Katiyar SK, Castanheira M, Pfaller MA, Edlind TD. 2011. Candida glabrata mutants demonstrating paradoxical caspofungin reduced susceptibility but micafungin increased susceptibility. Antimicrob. Agents Chemother. 55:3947-3949. http://dx.doi.org/10.1128/AAC.00044-11.
10. Lepak A, Castanheira M, Diekema D, Pfaller M, Andes D. 2012. Optimizing echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations. Antimicrob. Agents Chemother. 56: 5875-5882. http://dx.doi.org/10. 1128/AAC.01102-12.
11. Arendrup MC, Cuenca-Estrella M, Lass-Florl C. 2012. EUCAST technical note on the EUCAST definitive document EDef 7.2: Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeastsEDef7.2(EUCAST-AFST).Clin. Microbiol. Infect. 18:E246- E247. http://dx.doi.org/10.1111/j.1469-0691.2012.03880.x.
12. Arendrup MC, Perlin DS, Jensen RH, Howard SJ, Goodwin J, Hope W. 2012. Differential in vivo activity of anidulafungin, caspofungin, and micafungin against C. glabrata with and without FKS resistance mutations. Antimicrob. Agents Chemother. 56:2435-2442. http://dx.doi.org/10.1128/AAC.06369-11.
13. Perlin DS. 2007. Resistance to echinocandin-class antifungal drugs. Drug Resist. Updat. 10:121-130. http://dx.doi.org/10.1016/j.drup.2007.04.002.
14. Arendrup MC, Rodriguez-Tudela JL, Park S, Garcia-Effron G, Delmas G, Cuenca-Estrella M, Gomez-Lopez A, Perlin DS. 2011. Echinocandin susceptibility testing of Candida spp. using EUCAST EDef 7.1 and CLSI M27-A3 standard procedures: Analysis of the influence of bovine serum albumin supplementation, storage time, and drug lots. Antimicrob. Agents Chemother. 55:1580-1587. http://dx.doi.org/10.1128/AAC.01364-10.